Listen to this episode from Caris Molecular Minute Podcasts on Spotify. Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Stephen Liu, Associate Professor of Medicine at Georgetown University and Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Together they discuss the updated results of…
Breaking News:Georgetown’s Cancer Center Awarded Top Designation by Federal Government Designation as Comprehensive Cancer Center Consortium Includes John Theurer Cancer Center The National Cancer Institute…
The available approved anti-cancer drugs for Chinese patients are relatively limited because of China’s low participation rate in international clinical trials. Therefore, a focus on…
Immune checkpoint inhibitor (ICI)-based treatment has become standard treatment for advanced non-small cell lung cancer (NSCLC) patients. We aimed to reveal the survival benefit of…
MedStar Health, D.C. Lung Cancer Conference 2024, 10/19/2024 7:30:00 AM – 10/19/2024 5:00:00 PM, This one-day multidisciplinary conference will provide a comprehensive update on recent…
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Specific genetic alterations, such as MET exon 14 (METex14) skipping, have been…
R0 resection and radiation therapy have been associated with improved OS in thymic carcinoma (TC) patients. Here we analyzed which subgroups of patients derive the…
PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with…
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2% to 7% of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK…
2024 Texas Lung Cancer Conference Agenda @TLCconference #TexasLung24
Immune checkpoint inhibitor (ICI)’s targeting the programmed-death-1/programmed-death ligand 1 (PD-1/PD-L1) axis have established themselves as part of the first line management of metastatic non-small cell…
